Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05033990 · ClinicalTrials.gov registry record
SPIROMICS Study of Early COPD Progression (SOURCE)
A clinical trial of COPD, Early-Onset, sponsored by University of Massachusetts, Worcester.
- Recruiting
- Registry status
- 1,000
- Enrollment target
- 14
- Study locations
NCT05033990: Recruiting study of COPD, Early-Onset, sponsored by University of Massachusetts, Worcester.
NCT05033990 is a study of COPD, Early-Onset that is actively recruiting participants, run by University of Massachusetts, Worcester. The registered enrollment target is 1,000 participants. The trial reports 14 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05033990, a study of COPD, Early-Onset, is actively recruiting participants, sponsored by University of Massachusetts, Worcester.
- RECRUITING
- Registry status
- 1,000 participants
- Enrollment target
- 14
- Study locations
Study Summary
This is an observational study of 1000 participants to further define the nature of early chronic obstructive pulmonary disease (COPD) in younger, at-risk individuals. The study has three main goals: * To use CT scan imaging to identify which smokers will develop COPD. * To identify biomarkers predictive of smokers that will develop COPD. * To determine if sputum (phlegm) can be analyzed to predict which smokers will develop COPD. Procedures (methods): All participants will undergo study related questionnaires assessing medical history, smoke exposure and use, medication use, social and behavioral health, pulmonary symptoms, food frequency, and will provide nasal swab, blood, stool, and urine samples, pulmonary function testing to determine function, sputum induction to provide a sputum sample for airway biospecimen analysis, and CT imaging of the lungs.
Primary Outcome
Parametric Response Mapping captures the change in lung density between matched inspiratory and expiratory images thereby enabling the distinction between normal lung parenchyma (PRMNORM), emphysema (PRMEMPH), and non-emphysematous air trapping referred to as functional small airway disease (PRMfSAD).
Conditions Studied
Study Locations (14)
California
- University of California Los Angeles - Los Angeles
- University of California, San Francisco - San Francisco
New York
- Columbia University - New York
- Weill Cornell Medical Center - New York
Alabama
- University of Alabama at Birmingham - Birmingham
Arizona
- Mayo Clinic Arizona - Scottsdale
Colorado
- National Jewish Health - Denver
Illinois
- University of Illinois Chicago - Chicago
Iowa
- University of Iowa - Iowa City
Maryland
- Johns Hopkins Bayview Medical Center - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,000 participants |
| Start Date | 2021-09-08 |
| Est. Completion | 2026-04 |
What NCT05033990 shows while recruiting
NCT05033990 is an observational study that tracks outcomes without assigning an intervention. Its 1,000 participants enrollment target places it among the larger protocols in the corpus.
The record links to 1 condition, with COPD, Early-Onset appearing as the primary indexed condition, and to 0 interventions.
NCT05033990 lists 14 locations in 12 states (California, New York, Alabama).
Frequently Asked Questions
What is clinical trial NCT05033990 about?
NCT05033990 is a clinical study titled "SPIROMICS Study of Early COPD Progression (SOURCE)". This is an observational study of 1000 participants to further define the nature of early chronic obstructive pulmonary disease (COPD) in younger, at-risk individuals. The study has three main goals: * To use CT scan imaging to identify which smokers will develop COPD. * To identify biomarkers pre...
What is the current status of trial NCT05033990?
This trial is currently recruiting. The enrollment target is 1,000 participants. The study started on 2021-09-08. Estimated completion is 2026-04.
What conditions does trial NCT05033990 study?
This clinical trial studies the following conditions: COPD, Early-Onset.
Who is sponsoring clinical trial NCT05033990?
This trial is sponsored by University of Massachusetts, Worcester, which has 240 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05033990 being conducted?
This trial has 14 study locations across Alabama, Arizona, California, Colorado, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00018044 · 1,000 participants
Study of Mycobacterial Infections
- NCT01036581 · 1,000 participants · NA
Advanced Functional and Structural MRI Techniques for Neuropharmacological Imaging
- NCT01192048 · 1,000 participants
Genetics of Congenital Heart Disease
- NCT01553214 · 1,000 participants · Phase 4
Improving White Blood Cell Collection From Healthy Donors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI